Dr. Khalil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7544 Medical Dr
Ste B
Gloucester, VA 23061Phone+1 804-693-9037Fax+1 804-693-9486
Education & Training
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2004 - 2007
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2001 - 2004
- Albert Einstein College of Medicine, Yeshiva UniversityPhD, 1993 - 2001
- Albert Einstein College of MedicineClass of 2001
- Albert Einstein College of Medicine, Yeshiva UniversityMS, 1993 - 1995
- Barnard College, Columbia UniversityBA, 1989 - 1993
Certifications & Licensure
- VA State Medical License 2011 - 2024
- NY State Medical License 2007 - 2012
- NJ State Medical License 2007 - 2011
- PA State Medical License 2001 - 2008
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Practice Excellence Award Riverside Medical Group, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Nominated for the 2007 NCCN Fellows Recognition Program 2007
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsAnti-CD40 agonist antibodies: preclinical and clinical experienceMagi Khalil, Robert H. Vonderheide
Update on Cancer Therapeutics. 2007-06-01 - 35 citationsT Cell Studies in a Peptide-Induced Model of Systemic Lupus ErythematosusMagi Khalil, Kayo Inaba, Ralph M. Steinman, Jeffrey V. Ravetch, Betty Diamond
Journal of Immunology. 2001-02-01 - 21 citationsThe naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus.Chuansheng Wang, Magi Khalil, Jeffrey V. Ravetch, Betty Diamond
Journal of Immunology. 2003-05-01
Journal Articles
- Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient...Vonderheide, R.H., LoRusso, P.M., Khalil, M., Gartner, E.M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J.A., Rüter, J., Mariani, G.L., Usari, T., Domchek, S.M., Clin Cancer Res, 1/1/2010
- Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablastsKim, S.J., Caton, M., Wang, C., Khalil, M., Zhou, Z., Hardin, J., and Diamond, B., J. of Exp. Med., 1/1/2008
- Clinical Activity and Immune Modulation in Cancer Patients Treated with CP-870,893, A Novel CD40 Agonist Monoclonal AntibodyVonderheide, R.H., Flaherty, K.T., Khalil, M., Schachter, M.S., Bajor, M., Gallagher, M., Sullivan, P., Mahaney, J.J., O’Dwyer, P., Huhn, R.D., and Antonia, S.J., J. Clin. Onc., 1/1/2007
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer.Vonderheide, R.H., LoRusso, P.M., Khalil, M., Heath, E., Khaira, D., Soulieres, D., Dorazio, P., Mariani, G.L., Usari, T., and Domchek, S.M., Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, 5/29/2009
- “The Role of EGFR in the Prognosis and Treatment of NSCLC”Khalil MM, MSKCC Junior Faculty Conference, Basking Ridge, NJ, 12/16/2008
- “Clinical Activity and Immune Modulation in Cancer Patients Treated with a Novel CD40 Agonist Monoclonal Antibody”Khalil MM, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 12/18/2006
- Join now to see all
Press Mentions
- Institute for Clinical Immuno-Oncology (ICLIO) Delivers Immunotherapy Education in the Community SettingJune 7th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: